Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Haematology > ASH 2022 > Various Topics > Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Presented by
Prof. Mark Walters; Prof. Franco Locatelli
Conference
ASH 2022
Trial
LTF-303
Doi
https://doi.org/10.55788/04c0273a
    Patients with transfusion-dependent β-thalassaemia (TDT) showed durable transfusion independence up to 8 years after a betibeglogene autotemcel (beti-cel) infusion, with an acceptable safety profile. Beti-cel transduction efficiency appeared to be the most predictive attribute of transfusion independence. Moreover, a different study displayed long-term quality-of-life improvements in patients with TDT who had received beti-cel infusion therapy.

    Prof. Mark Walters (University of California, CA, USA) presented up to 8 years of follow-up efficacy and safety data of 63 patients with TDT who received beti-cel infusion therapy [1]. Transfusion independence was defined as a haemoglobin (Hb) level ≥9 g/dL without packed red blood cell transfusions for ≥12 months.

    The peripheral blood vector copy number (VCN) per cell was stable and durable over time, especially in phase 3 studies, in which patients received optimised beti-cel infusion doses. Similarly, total Hb levels and therapy-derived HbA-T87Q levels were stable and durable (mean of approximately 12 g/dL and 9 g/dL) for patients who were included in phase 3 studies. Prof. Walters showed that the effect was independent of age and genotype. Furthermore, an exploratory analysis suggested that a percentage of 62% transduced cells increased the likelihood of achieving transfusion independence. Finally, 19% of the patients in phase 3 trials had ≥1 adverse event (AE) possibly related to beti-cel infusion therapy. Hepatic veno-occlusive disease occurred in 11% of the patients, but these events were resolved after treatment.

    In another presentation, Prof. Franco Locatelli (University of Rome, Italy) reported the 3-year follow-up data of the LTF-303 study (NCT02633943), that investigated patient-reported outcomes in patients with TDT who received beti-cel infusion therapy (n=57) [2]. For patients who had reached transfusion independence, the SF-36 physical component score and mental component score were 55.7 and 56.3 at 3 years, which was a raise from the baseline levels of 53.8 and 50.9, respectively. A slight drop in SF-36 scores was observed in patients who had not achieved transfusion independence. In paediatric patients who reached transfusion independence (n=22), the mean PedsQL total score increased from 78.3 at baseline to 90.6 at 3 years. For those who did not achieve transfusion independence, no change in mean PedsQL total score was reported. Three years after treatment, data showed positive trends in employment/employment seeking rates (67% to 93%), school absence (95% to 50%), and physical activity (+81% improvement).

    Thus, durable transfusion independence and quality-of-life improvements were reported in patients with TDT who received beti-cel infusion therapy.

    1. Walters MC, et al. Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials. Abstract 2348, ASH 64th Annual Meeting, 10–13 December 2022, New Orleans, LA, USA.
    2. Locatelli F, et al. Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia. Abstract 3665, ASH 64th Annual Meeting, 10–13 December 2022, New Orleans, LA, USA.

    Copyright ©2023 Medicom Medical Publishers



    Posted on